Hyperammonemia (Hereditary)

Overview

Plain-Language Overview

Hereditary hyperammonemia is a rare genetic condition that affects the body's ability to remove ammonia, a waste product, from the blood. The condition primarily involves the liver and the metabolic system, where ammonia is normally converted into urea and safely eliminated. When this process is disrupted, ammonia builds up in the bloodstream, which can be toxic to the brain and cause serious health problems. Symptoms often include confusion, vomiting, and in severe cases, loss of consciousness or coma. Early diagnosis and management are crucial to prevent long-term brain damage and other complications.

Clinical Definition

Hereditary hyperammonemia is a metabolic disorder characterized by elevated blood ammonia levels due to inherited defects in the urea cycle enzymes, most commonly ornithine transcarbamylase (OTC) deficiency. This leads to impaired conversion of ammonia to urea, resulting in toxic accumulation of ammonia in the blood and subsequent neurotoxicity. The condition is usually caused by mutations in genes encoding urea cycle enzymes such as OTC, CPS1, ASS1, and others. Clinically, it presents with acute encephalopathy, vomiting, lethargy, and can progress to seizures and coma if untreated. It is a critical diagnosis in neonates and children presenting with unexplained neurological symptoms and elevated ammonia. Early recognition and intervention are essential to prevent irreversible brain injury and death.

Inciting Event

Infection or febrile illness often triggers acute hyperammonemic crisis.
High protein meal or increased protein catabolism precipitates symptoms.
Surgery or trauma can induce catabolic state leading to ammonia accumulation.
Certain drugs such as valproic acid or chemotherapy agents may provoke hyperammonemia.

Latency Period

Symptoms typically develop within hours to days after the inciting event in neonates.
In partial deficiencies, latency can be weeks to years before first hyperammonemic episode.
Acute crises often present rapidly after metabolic stress with progressive encephalopathy.

Diagnostic Delay

Symptoms are often misattributed to sepsis or meningitis in neonates.
Lack of awareness of urea cycle disorders leads to delayed ammonia measurement.
Normal liver function tests may mislead clinicians away from metabolic causes.
Intermittent symptoms in partial deficiencies cause diagnostic uncertainty.

Clinical Presentation

Signs & Symptoms

Lethargy, vomiting, and poor feeding in neonates with urea cycle defects
Progressive encephalopathy with confusion, seizures, and coma in untreated cases
Hyperventilation due to respiratory compensation for metabolic acidosis
Irritability and behavioral changes in older children and adults
Protein intolerance and episodic vomiting triggered by high protein intake or catabolic stress

History of Present Illness

Rapid onset of vomiting, lethargy, and irritability progressing to coma in neonates.
Older children may report episodic confusion, ataxia, and behavioral changes.
History of hyperventilation and seizures during acute episodes is common.
Symptoms worsen after protein-rich meals or catabolic stress.

Past Medical History

Previous episodes of unexplained encephalopathy or altered mental status.
History of failure to thrive or developmental delay in infants.
Prior use of valproic acid or other mitochondrial toxins.
No significant liver disease despite elevated ammonia levels.

Family History

Male relatives with neonatal death or unexplained coma suggest X-linked OTC deficiency.
Relatives with recurrent unexplained encephalopathy or psychiatric symptoms.
Known family members diagnosed with urea cycle disorders.
Consanguinity increases risk of autosomal recessive urea cycle enzyme deficiencies.

Physical Exam Findings

Altered mental status ranging from confusion to coma due to neurotoxicity of elevated ammonia
Hyperreflexia and spasticity reflecting cerebral edema and neuronal dysfunction
Asterixis (flapping tremor) indicating hepatic encephalopathy-like presentation
Tachypnea as a compensatory response to metabolic acidosis from ammonia accumulation
Hepatomegaly may be present if associated with liver dysfunction or secondary liver disease

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by detecting elevated plasma ammonia levels in the setting of normal liver function tests. Confirmatory testing includes measurement of plasma amino acids showing characteristic patterns such as elevated glutamine and low citrulline, and urinary orotic acid levels, which are elevated in OTC deficiency. Genetic testing for mutations in urea cycle enzyme genes such as OTC confirms the diagnosis. Enzyme activity assays in liver biopsy may be used in uncertain cases. Early diagnosis relies on a combination of clinical suspicion, biochemical testing, and molecular confirmation.

Pathophysiology

Key Mechanisms

Deficiency of a urea cycle enzyme, most commonly ornithine transcarbamylase (OTC), leads to impaired conversion of ammonia to urea.
Accumulation of toxic ammonia in the blood causes cerebral edema and neurotoxicity.
Disruption of the urea cycle results in elevated plasma ammonia and altered amino acid metabolism.
Excess ammonia crosses the blood-brain barrier, causing astrocyte swelling and increased intracranial pressure.
Secondary glutamine accumulation in astrocytes contributes to osmotic imbalance and neuronal dysfunction.

Involvement	Details
Organs	Liver is the central organ involved in ammonia detoxification via the urea cycle, and its dysfunction causes hyperammonemia.
	Kidneys excrete alternative nitrogen waste products formed by pharmacological agents like sodium benzoate and phenylacetate.
	Brain is the target organ for ammonia toxicity, manifesting as altered mental status, seizures, and coma.
Tissues	Liver tissue is critical as the site of the urea cycle where ammonia is converted to urea for excretion.
Tissues	Brain tissue is affected by ammonia toxicity leading to cerebral edema and encephalopathy in hyperammonemia.
Cells	Hepatocytes are the primary cells responsible for urea cycle function and ammonia detoxification in the liver.
Cells	Astrocytes in the brain metabolize ammonia to glutamine, and their swelling contributes to cerebral edema in hyperammonemia.
Chemical Mediators	Ammonia is the toxic metabolite that accumulates due to urea cycle enzyme deficiencies causing neurological symptoms.
	Glutamine accumulates in astrocytes during hyperammonemia, leading to osmotic swelling and brain edema.
	Carbamoyl phosphate synthetase I is a key enzyme activated by carglumic acid to enhance urea cycle activity.

Treatments

Pharmacological Treatments

Sodium benzoate
- Mechanism:
  - Conjugates with glycine to form hippurate, facilitating alternative nitrogen excretion.
- Side effects:
  - Metabolic acidosis
  - Gastrointestinal upset
  - Hypokalemia
- Clinical role:
  - First-line
Sodium phenylacetate
- Mechanism:
  - Binds glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels.
- Side effects:
  - Neurotoxicity
  - Hypokalemia
  - Hypotension
- Clinical role:
  - First-line
Arginine supplementation
- Mechanism:
  - Provides substrate to enhance residual urea cycle function and promote ammonia detoxification.
- Side effects:
  - Hyperkalemia
  - Gastrointestinal discomfort
- Clinical role:
  - Adjunctive
Carglumic acid
- Mechanism:
  - Activates carbamoyl phosphate synthetase I to enhance urea cycle activity in N-acetylglutamate synthase deficiency.
- Side effects:
  - Vomiting
  - Headache
  - Fever
- Clinical role:
  - Second-line

Non-pharmacological Treatments

Implement a protein-restricted diet to reduce ammonia production from amino acid catabolism.
Provide intravenous glucose to suppress catabolism and reduce endogenous ammonia generation.
Perform hemodialysis or continuous renal replacement therapy in severe hyperammonemia to rapidly remove ammonia.
Liver transplantation may be considered for definitive treatment in severe or refractory cases.

Prevention

Pharmacological Prevention

Sodium benzoate and sodium phenylacetate to enhance alternative nitrogen excretion pathways
L-arginine supplementation to support urea cycle function in certain enzyme deficiencies
Carglumic acid as a synthetic analog of N-acetylglutamate to activate carbamoyl phosphate synthetase I
Ammonia scavengers to prevent hyperammonemia during metabolic stress
Avoidance of valproic acid which can exacerbate hyperammonemia

Non-pharmacological Prevention

Protein-restricted diet tailored to reduce ammonia production while maintaining nutrition
Prompt treatment of infections and catabolic stressors to prevent metabolic decompensation
Regular monitoring of plasma ammonia and amino acids for early detection of crises
Genetic counseling and prenatal diagnosis for families with known urea cycle defects
Avoidance of prolonged fasting to reduce endogenous protein catabolism

Outcome & Complications

Complications

Cerebral edema leading to increased intracranial pressure and herniation
Permanent neurological damage including intellectual disability and motor deficits
Seizures refractory to standard anticonvulsants
Respiratory failure from brainstem dysfunction
Death if untreated or diagnosis delayed

Short-term Sequelae	Long-term Sequelae
Acute encephalopathy with confusion, vomiting, and seizures Metabolic crisis triggered by infection, fasting, or high protein intake Respiratory alkalosis due to hyperventilation Hypoglycemia from impaired gluconeogenesis during acute episodes Electrolyte imbalances such as hyponatremia	Chronic intellectual disability from repeated ammonia neurotoxicity Motor deficits including spasticity and ataxia Behavioral and psychiatric disorders secondary to brain injury Growth retardation due to chronic illness and dietary restrictions Chronic liver disease in some urea cycle disorders with hepatic involvement

Differential Diagnoses

Hyperammonemia (Hereditary) versus Liver Failure

Hyperammonemia (Hereditary)	Liver Failure
Normal liver enzymes with isolated hyperammonemia	Elevated liver enzymes (AST, ALT), elevated bilirubin, prolonged PT/INR
Acute or chronic hyperammonemia without primary liver dysfunction	Progressive hepatic dysfunction with multisystem involvement
Normal liver imaging with enzyme deficiencies in urea cycle enzymes	Imaging showing cirrhosis or hepatic necrosis

Hyperammonemia (Hereditary) versus Urea Cycle Disorders (Other than OTC Deficiency)

Hyperammonemia (Hereditary)	Urea Cycle Disorders (Other than OTC Deficiency)
X-linked recessive inheritance	Autosomal recessive inheritance
Deficiency of ornithine transcarbamylase enzyme	Deficiency of enzymes such as carbamoyl phosphate synthetase I or argininosuccinate lyase
Elevated orotic acid with low citrulline	Elevated citrulline or argininosuccinate levels depending on enzyme affected

Hyperammonemia (Hereditary) versus Organic Acidemias (e.g., Propionic Acidemia, Methylmalonic Acidemia)

Hyperammonemia (Hereditary)	Organic Acidemias (e.g., Propionic Acidemia, Methylmalonic Acidemia)
Normal acid-base status with isolated hyperammonemia	Metabolic acidosis with elevated anion gap and elevated organic acids in urine
Variable onset, often triggered by protein load or stress	Neonatal onset with severe metabolic crisis including vomiting and lethargy
Elevated plasma ammonia with normal organic acid profile	Elevated methylmalonic acid or propionic acid in plasma/urine

Hyperammonemia (Hereditary) versus Transient Hyperammonemia of the Newborn

Hyperammonemia (Hereditary)	Transient Hyperammonemia of the Newborn
Can present at any age depending on enzyme deficiency	Occurs in premature neonates shortly after birth
Chronic or recurrent hyperammonemia requiring lifelong management	Self-limited with resolution as liver matures
Deficient urea cycle enzyme activity	Normal urea cycle enzyme activity

Hyperammonemia (Hereditary) versus Reye Syndrome

Hyperammonemia (Hereditary)	Reye Syndrome
No aspirin exposure, hereditary enzyme defect	Recent viral illness with aspirin use
Normal liver enzymes with isolated hyperammonemia	Elevated liver enzymes, hypoglycemia, prolonged PT
Variable onset with episodic hyperammonemia	Acute encephalopathy with rapid progression after viral illness